Latest News and Press Releases

Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...

Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering. The global oncologists...

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights...

Wilmington, Delaware, United States, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - Head and neck cancer market was valued at US$ 1.6 billion in 2022. A CAGR of 6.8% is...

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong...

HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were...

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with...

Dublin, July 25, 2023 (GLOBE NEWSWIRE) -- The "Radiation Oncology Market Size, Share & Trends Analysis Report By Type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), By...

Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Oncology Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global revenue for...

14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed...